ARCHIVES

Dasatinib, Nilotinib Show Strong Early Results As Frontline Therapy For CML

This article is from The Cancer Letter archive.

Vol. 30 No. 12 | December 28, 2007

Download PDF Visit The Full Archive

Related Articles

NCI to Expand Quality of Care Research, Lead HHS Panel On Cancer Care Policy.

October 1, 1999

Duke Scores Highest On NCAB Review

July 14, 1978

FDA Says Medicare Policy On ESAs “Consistent With The Available Data.”

October 19, 2007

NCI blocked groups from phase III Iressa studies.

April 30, 2004

Taxol Patents Reveal Bristol Strategy to Safeguard Market Against Competitors

July 4, 1997

Satraplatin Improved PFS In Refractory Prostate Cancer

July 25, 2003